



(12) Translation of
European patent specification

(11) NO/EP 2273876 B1

NORWAY

(19) NO
(51) Int Cl.
A01N 33/02 (2006.01)
A61K 9/06 (2006.01)
A61K 31/13 (2006.01)
A61K 31/74 (2006.01)
A61K 47/10 (2017.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.05.06
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.03.06
(86)	European Application Nr.	09724939.5
(86)	European Filing Date	2009.03.11
(87)	The European Application's Publication Date	2011.01.19
(30)	Priority	2008.03.27, US, 3984008 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(73)	Proprietor	Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Lugano-Pazzallo, Sveits
(72)	Inventor	ALONSO, Robert, Yaupon Therapeutics Inc.259 N. Radnor-chester RoadSuite 205, Radnor, PA 19087-5259, USA WALKER, Barry, R., Yaupon Therapeutics Inc.259 NRadnor-chester RoadSuite 205, Radnor, PA 19087-5259, USA CROOKS, Peter, A., Univ. Of KentuckyCollege Of Pharmacy501-B Pharmacy Bldg.907 Rose St., Lexington, KY 40536-0082, USA
(74)	Agent or Attorney	PROTECTOR IP AS, Oscars gate 20, 0352 OSLO, Norge

(54)	Title	STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME
(56)	References Cited:	US-A- 5 948 437, US-A1- 2006 205 694, US-A- 6 005 002, US-B2- 7 323 171, US-A1- 2007 287 719

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Farmasøytisk sammensetning bestående av:
0,02 masse-% mekloretoamin hydroklorid;
2,00 masse-% hydroksypropyl cellulose;
5 0,01 masse-% edetat dinatrium dihydrat;
0,05 masse-% racemisk mentol;
0,01 masse-% butylert hydroksytoluen;
49,91 masse-% 2-(2-etoksy-etoksy)etanol;
15,27 masse-% isopropyl alkohol;
10 17,57 masse-% propylen glykol;
11,33 masse-% glyserin;
3,65 masse-% racemisk melkesyre; og
0,18 masse-% natrium klorid.
2. Sammensetning i henhold til krav 1 for anvendelse ved behandling av
15 en hudlidelse.
3. Sammensetning for anvendelse i henhold til krav 2, hvor hudlidelsen
er valgt fra gruppen bestående av psoriasis, eksem, aktinisk keratose,
lupus, sarkoidose, håravfall, kutan T-celle lymfom (det vil si mucosis
fungoides), lymforetikular neoplasia, pleurale og peritoneale effusjoner,
20 kutan B-celle lymfom, pseudolymfomas av huden, skjell celle
karsinom, basal celle karsinom, bronkogen karsinom, malignant
melanom, lymfosarkoma, kronisk lymfocytisk leukemi, polycytemi
vera, lymfomatoid papulose, Mucha-Habbermanns lidelse, vitiligo, og
kombinasjoner derav.
- 25 4. Sammensetning for anvendelse i henhold til krav 3, hvor hudlidelsen
er vitiligo.
5. Sammensetning for bruk i henhold til krav 3, hvor hudlidelsen er kutan
T-celle lymfoma (det vil si mycosis fungoides).